Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 89 Neoplasms 6 HER2-positive Breast Cancer 5 Triple Negative Breast Neoplasms 4 Prostatic Neoplasms 4 Ovarian Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Stomach Neoplasms 3 Neoplasm Metastasis 3 Multiple Myeloma 3 Colorectal Neoplasms 3 Urinary Bladder Neoplasms 2 Rectal Neoplasms 2 Pathologic Complete Response 2 Pancreatic Neoplasms 2 Lymphoma, Non-Hodgkin 2 Lung Neoplasms 2 Locally Advanced Breast Cancer 2 Inflammatory Breast Neoplasms 2 Colonic Neoplasms 2 Brain Neoplasms 2 Biliary Tract Neoplasms 2 Anatomic Stage I Breast Cancer AJCC v8 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Thyroid Neoplasms 1 Solid Cancers 1 Salivary Gland Neoplasms 1 Neuroendocrine Tumors 1 Neuroblastoma 1

Interventions

Gemcitabine 9 Carboplatin 8 Paclitaxel 6 Capecitabine 4 Bevacizumab 4 pembrolizumab 3 Irinotecan 3 Erlotinib Hydrochloride 3 atezolizumab 2 Peripheral Blood Stem Cell Transplantation 2 Oxaliplatin 2 Filgrastim 2 Cisplatin 2 CP protocol 2 tislelizumab 1 tegafur-gimeracil-oteracil 1 spartalizumab 1 sintilimab 1 pertuzumab 1 pemigatinib 1 olaparib 1 ivosidenib 1 ipatasertib 1 etoposide phosphate 1 entrectinib 1 cobimetinib 1 belinostat 1 antineoplaston AS 2-1 1 antineoplaston A10 1 alectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasms, Unknown Primary × pertuzumab × Clear all

NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡